Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade

Wang, Yangyang; Huang, Bolin; Fu, Qihan; Wang, Jianbo; Ye, Mao; Hu, Manyi; Qu, Kai; Li, Kai; Hu, Xiao; Wei, Shumei; Sun, Ke; Xiao, Wen-Li; Zhang, Bo; Li, Haijun; Li, Jingsong; Zhang, Qi; Liang, Tingbo

doi:10.1245/s10434-022-12107-w

Cited by 8 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the, 2019 World Health Organization classification of gastroenteropancreatic NENs, these neoplasms are divided into three grades based on mitotic rate and Ki-67 index: Well-differentiated neuroendocrine tumors (NETs), poorly-differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) ( 29 ). In contrast to NENs in the pancreas and appendix, which predominantly belong to the G1/G2 grades, the majority of GB-NENs are found to be malignant neuroendocrine carcinomas, closely associated with a poorer prognosis ( 30 , 31 ). Immunohistochemical markers such as Ki-67, chromogranin A (CgA), synaptophysin (Syn), and neuron specific enolase (NSE) play a crucial role in the diagnosis of NENs ( 17 ).…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Comparative prognosis and risk assessment in gallbladder neuroendocrine neoplasms versus adenocarcinomas

Zhao,

Huang,

Jiang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundGallbladder neuroendocrine neoplasms (GB-NENs) are a rare malignant disease, with most cases diagnosed at advanced stages, often resulting in poor prognosis. However, studies regarding the prognosis of this condition and its comparison with gallbladder adenocarcinomas (GB-ADCs) have yet to yield convincing conclusions.MethodsWe extracted cases of GB-NENs and GB-ADCs from the Surveillance, Epidemiology, and End Results (SEER) database in the United States. Firstly, we corrected differences in clinical characteristics between the two groups using propensity score matching (PSM). Subsequently, we visualized and compared the survival outcomes of the two groups using the Kaplan-Meier method. Next, we employed the least absolute shrinkage and selection operator (LASSO) regression and Cox regression to identify prognostic factors for GB-NENs and constructed two nomograms for predicting prognosis. These nomograms were validated with an internal validation dataset from the SEER database and an external validation dataset from a hospital. Finally, we categorized patients into high-risk and low-risk groups based on their overall survival (OS) scores.ResultsA total of 7,105 patients were enrolled in the study, comprising 287 GB-NENs patients and, 6,818 GB-ADCs patients. There were substantial differences in clinical characteristics between patients, and GB-NENs exhibited a significantly better prognosis. Even after balancing these differences using PSM, the superior prognosis of GB-NENs remained evident. Independent prognostic factors selected through LASSO and Cox regression were age, histology type, first primary malignancy, tumor size, and surgery. Two nomograms for prognosis were developed based on these factors, and their performance was verified from three perspectives: discrimination, calibration, and clinical applicability using training, internal validation, and external validation datasets, all of which exhibited excellent validation results. Using a cutoff value of 166.5 for the OS nomogram score, patient mortality risk can be identified effectively.ConclusionPatients with GB-NENs have a better overall prognosis compared to those with GB-ADCs. Nomograms for GB-NENs prognosis have been effectively established and validated, making them a valuable tool for assessing the risk of mortality in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 94%

“…In a recent multicenter retrospective study led by Wang et al. ( 31 ), GB-NENs demonstrated 1, 3, and 5-year survival rates of 59%, 33%, and 29%, respectively. It is worth mentioning that this study included 8.3% of NETs cases.…”

Section: Discussionmentioning

confidence: 99%

Comparative prognosis and risk assessment in gallbladder neuroendocrine neoplasms versus adenocarcinomas

Zhao,

Huang,

Jiang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…We retrospectively searched 154 patients with pathological confirmed primary GB-NENs in 143 hospitals in China from 2004 to 2021. 4 Owing to the large volume, we were able to obtain a general picture of this rare disease. More than a half of patients were found at advanced stage, and 62.3% patients had poorly differentiated neuroendocrine carcinomas.…”

Section: Presentmentioning

confidence: 99%

ASO Author Reflections: Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms

2022

Self Cite

View full text Add to dashboard Cite

“…The 4 phases' findings of the CT raised the possibility of a gallbladder tumor. 1,2 FIGURE 2. The patient participated in the 68 Ga-FAPI (fibroblast activation protein inhibitor) solid tumor clinical trial (CZLS2021027-A) approved by the institutional review committee of our hospital.…”

mentioning

confidence: 99%

“…Delayed phase images ( D ) showed slightly reduced enhancement in the lesion (arrow) with a mean Hounsfield unit of 65.6. The 4 phases' findings of the CT raised the possibility of a gallbladder tumor 1,2 …”

mentioning

confidence: 99%

Increased 68Ga-FAPI Activity in Primary Small Cell Neuroendocrine Carcinoma of the Gallbladder

Chen,

Sun,

Liu

et al. 2023

Clin Nucl Med

View full text Add to dashboard Cite

Primary small cell neuroendocrine carcinomas are extremely rare heterogeneous neoplasms. We present 68Ga-FAPI (fibroblast activation protein inhibitor) PET/CT findings of small cell neuroendocrine carcinoma of the gallbladder in a 57-year-old woman. This rare gallbladder small cell neuroendocrine carcinoma demonstrated intense tracer uptake on 68Ga-FAPI PET/CT. This demonstrates the potential value of 68Ga-FAPI PET/CT for evaluation of gallbladder small cell neuroendocrine carcinoma.

show abstract

Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade

Cited by 8 publications

References 46 publications

Comparative prognosis and risk assessment in gallbladder neuroendocrine neoplasms versus adenocarcinomas

Comparative prognosis and risk assessment in gallbladder neuroendocrine neoplasms versus adenocarcinomas

ASO Author Reflections: Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms

Increased 68Ga-FAPI Activity in Primary Small Cell Neuroendocrine Carcinoma of the Gallbladder

Contact Info

Product

Resources

About